A left turn toward a socialist health care system? That’s what Democrats in Washington are trying to do with their latest push for socialist ‘delinking’ policies.
Experts, including Matrix Global Advisors founder and CEO Alex Brill and University of Chicago Professor of Economics Casey Mulligan, Ph.D., are warning against the disastrous consequences of these policies.
In each analysis, the authors explain how ‘delinking’ policies would use the heavy hand of the government to restrict pharmacy benefit managers (PBMs) by banning market-based incentives that deliver lower prescription drug costs for patients, American businesses and taxpayers. The result?
- ‘Delinking’ would mean the government picking winners and losers, eliminating market-based incentives that deliver lower health care costs.
- Patients would be among the losers, with the passage of ‘delinking’ policies projected to cause premium hikes as high as $39.4 billion each year in the commercial market and Medicare.
- The hit to taxpayers would also be massive, with Mulligan’s analysis estimating ‘delinking’ would increase costs to taxpayers in the form of higher federal spending, by $3 to $10 billion annually.
If the Left gets their way, government ‘delinking’ would eliminate employers’ freedom to work with PBMs to leverage scale and competition to secure savings — hitting American businesses, their employees and taxpayers with unsustainable increases to their prescription drug costs.
The socialist Left would get more control over America’s health care, and everyone else would be hit with higher costs.
MORE government intervention is NOT the answer. We need Republican lawmakers to stop the Left’s ‘delinking’ assault on market forces in health care.
Stop ‘delinking’ policies that target pharmacy benefits!
